The maths was always going to catch up with the virtue-signallers. Yesterday, the United States confirmed it is withdrawing its HIV/AIDS funding from South Africa, a move that will leave a gaping hole in the country's health budget and send a clear signal to markets: global health leadership is not a cost-free good. The American taxpayer, already weary of footing the bill for pandemic-era largesse, has finally said 'enough'. And now, the burden falls squarely on Britain's shoulders.
Let's talk numbers. The US President's Emergency Plan for AIDS Relief (PEPFAR) has pumped something like $7 billion into South Africa over the years. That cash flow is about to be turned off like a tap. The South African rand, already a mercurial currency, will feel the shock. Capital flight is a real risk here: sovereign risk premiums will widen, and the Johannesburg Stock Exchange will take a hit. The markets do not like uncertainty, especially when it comes to government spending.
But the real story is the political vacuum. The World Health Organization, a bloated bureaucracy if ever there was one, is in no position to step in. Its credibility was shredded during the pandemic, and its budget is largely funded by US and European donations. The European Union is still licking its wounds from Brexit and its own fiscal crises. So who fills the void? Britain. The Department for International Development, now folded into the Foreign Office, will be expected to dig deep into its pockets. But the Treasury is already groaning under the weight of gilt issuance. The Debt Management Office is floating record amounts of government paper. How much more can the bond market stomach?
The irony is exquisite. Britain has spent years lecturing the world on fiscal responsibility while simultaneously printing money to prop up its own health service. Now it must decide whether to write a cheque for South Africa's antiretroviral drugs or face the geopolitical consequences of letting that country's HIV epidemic spiral. The Chancellor will be sweating. The 30-year gilt yield is already up 20 basis points this month on hints of further borrowing. This is not a sustainable trajectory.
What of South Africa? The African National Congress, a party that treats the fiscus as a slush fund, will howl about Western imperialism. But the truth is they have mismanaged their own health system for decades. Corruption in the procurement of pharmaceuticals is well documented. A rational investor would demand structural reforms before a single pound of British aid is committed. But the Foreign Office is not in the business of rational investment. It is in the business of burnishing the 'Global Britain' brand. That brand is about to become very expensive.
This is not just about HIV. It is about the architecture of international development finance. The US withdrawal signals a shift in the West's willingness to underwrite the health systems of developing nations. Countries like India and Brazil will be watching closely. They will calculate that if the US can walk away from South Africa, the same can happen to them. The result will be a scramble for alternative funding sources, possibly from China. Is Britain prepared to compete with the People's Bank of China's deep pockets? The Bank of England's balance sheet says no.
In the short term, I expect to see a spike in demand for UK aid bonds, but only if they carry some form of sovereign guarantee. That is a messy state of affairs. Markets prefer clean, transparent funding. They do not like coercive burden-sharing. The Mbeki-era denials of HIV science were a disgrace, but that does not mean the West should have to write blank cheques in perpetuity. The bottom line: the market is not a piggy bank. It is a brutal accountant. And right now, the accounts are flashing red.
Britain must decide whether it wants to be the world's health insurer or focus on its own economic recovery. It cannot do both. The rational choice is to offer technical assistance, not blank cheques. But rationality rarely governs foreign policy. Expect a headline-grabbing pledge from Downing Street within the week, followed by a quietly revised OBR forecast a few months later. That is the cycle we are stuck in. The market will price it in, as it always does.
